Structure Therapeutics reports new data on oral amylin and GLP-1 obesity drugs

Structure Therapeutics Inc. (NASDAQ: GPCR) reported on September 8, 2026 clinical trial results for its two lead oral small molecule candidates for chronic weight management, according to an 8-K filing.

For ACCG-2671, an oral dual amylin and calcitonin receptor agonist, the Phase 1 single ascending dose portion evaluated 31 healthy adult participants without obesity, who received single doses of 1, 2, 5, or 10 mg or placebo.¹ The drug showed rapid absorption with Tmax at 1 to 1.5 hours and a terminal half-life of approximately 6 days, supporting daily or weekly dosing evaluation.¹ The company said ACCG-2671 was generally well tolerated, with no serious adverse events, no drug-related discontinuations, and no liver injury events.¹ Dose-related gastrointestinal events emerged at 5mg, with nausea in 4 of 5 participants and vomiting in 3 of 5, and at 10 mg in all 6 participants.¹ A single 10 mg dose was associated with a 3.3% mean body weight reduction at Day 24, and CTX-1, a bone resorption biomarker, decreased about 60% by Day 2.¹ The company has begun dosing in the multiple ascending dose portion of the trial, with topline data expected in the first half of 2027.¹

For aleniglipron (GSBR-1290), an oral GLP-1 receptor agonist, participants originally randomized to 45 mg, 90 mg and 120 mg who dosed up to 180 mg in the ACCESS open-label extension achieved weight loss of 11.6%, 14.4% and 16.2% respectively at 72 weeks, with no plateau observed in the two top doses.¹ More than one-third of participants in the 90 mg and 120 mg cohorts lost more than 20% of body weight, with mean absolute losses of 35.9 and 40.5 pounds.¹ Treatment discontinuations due to adverse events occurred in fewer than 5% of OLE participants.¹

The Phase 3 ACCOMPLISH-1 trial (NCT07654361) is enrolling up to 3,600 adults with obesity or overweight and a weight-related comorbidity, while ACCOMPLISH-2 (NCT07654374) is enrolling up to 1,100 adults with obesity or overweight and type 2 diabetes, testing 45 mg, 90 mg or 180 mg maintenance doses after a 2.5 mg start.¹ Topline data are expected in the second half of 2028.¹